A Phase 3 interventional study of losartan potassium and Comparator: placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 27th largest by enrollment, is one of 2 that started in 1991, is one of 17 in phase 3, and was the 18th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 2 started in 1991.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
33 studies in Hypertension by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 33 finished, 27 (82%) have results posted.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 1991, is one of 9 in phase 3, and was the 11th registered.
Merck & Co., Inc’s Hypertension studies by the year they started, since 1990.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the magnitude and durations of the antihypertensive effects of losartan using ambulatory blood pressure monitoring (ABPM), and to evaluate the safety of losartan 50 and 100 mg doses compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Comparator: placebo · Drug: hydrochlorothiazide (HCTZ)
losartan 50 mg q.d.
Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)
losartan 100 mg q.d.
Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)
losartan 50 mg b.i.d.
Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)
losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Also known as: MK0954
placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
Also known as: HCTZ
Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
Time frame: 24 hour period at Baseline and Week 4
Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4
Time frame: 24-hour period at baseline and Week 4
Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4
Time frame: Baseline and 24-hours after morning dose at Week 4
Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6
Time frame: Baseline and 24-hours after morning dose at Week 6
Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6
Time frame: Baseline and 24-hours after morning dose at Week 6
Patients were recruited at 9 sites in the United States. Prime Therapy Period: May, 1991 to March, 1992.
| Milestone | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Started | 32 | 29 | 30 | 31 |
| Completed | 30 | 28 | 29 | 29 |
| Not completed | 2 | 1 | 1 | 2 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Started | 28 | 21 | 21 | 23 |
| Completed | 28 | 21 | 19 | 23 |
| Not completed | 0 | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| mm Hg | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | -0.2 ± 4.8 | -5.2 ± 5.1 | -6.4 ± 5.5 | -8.5 ± 6.7 |
| mm Hg | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring (ABPM) at Week 4 | 0 ± 7.8 | -9.2 ± 9.9 | -9.9 ± 7.6 | -13.2 ± 10.6 |
| mm Hg | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) 24 Hours After Morning Dose at Week 4 | -2.1 ± 6.9 | -6.7 ± 7.8 | -9.6 ± 6.5 | -8.8 ± 7.8 |
| mm Hg | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Mean Change From Baseline in Sitting Diastolic Blood Pressure (siDBP) After Adding HCTZ 24 Hours After Morning Dose at Week 6 | -4.6 ± 6.1 | -9.9 ± 6.3 | -10.7 ± 4.9 | -10.1 ± 7.8 |
| mm Hg | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg |
|---|---|---|---|---|
| Mean Change From Week 4 in Sitting Diastolic Blood Pressure (siDBP) Adding HCTZ 24 Hours After Morning Dose at Week 6 | -4.0 ± 6.4 | -5.1 ± 7.8 | -4.0 ± 6.1 | -4.0 ± 6.9 |
| Age, Continuous(years) | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | Total |
|---|---|---|---|---|---|
| Mean | 52.2 ± 12.0 | 56.8 ± 12.1 | 51.2 ± 9.6 | 54.1 ± 9.0 | 53.5 ± 10.8 |
| Sex: Female, Male(Participants) | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | Total |
|---|---|---|---|---|---|
| Female | 7 | 10 | 9 | 13 | 39 |
| Male | 25 | 19 | 21 | 18 | 83 |
| Race/Ethnicity(participants) | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | Total |
|---|---|---|---|---|---|
| Caucasian | 30 | 29 | 30 | 30 | 119 |
| Oriental | 0 | 0 | 0 | 1 | 1 |
| Filipino | 1 | 0 | 0 | 0 | 1 |
| Indian | 1 | 0 | 0 | 0 | 1 |
| Diastolic 24-hr mean ambulatory blood pressure monitoring (ABPM)(mm Hg) | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | Total |
|---|---|---|---|---|---|
| Mean | 94.8 ± 5.9 | 94.0 ± 6.9 | 93.8 ± 6.0 | 94.4 ± 6.9 | 94.2 ± 6.4 |
| Sitting Diastolic Blood Pressure (SiDBP)(mm Hg) | Placebo / HCTZ 12.5 mg | Losartan 50 mg q.d. / HCTZ 12.5 mg | Losartan 100 mg q.d. / HCTZ 12.5 mg | Losartan 50 mg b.i.d. / HCTZ 12.5 mg | Total |
|---|---|---|---|---|---|
| Mean | 100.7 ± 4.0 | 100.0 ± 4.6 | 101.5 ± 5.1 | 101.2 ± 4.8 | 100.9 ± 4.6 |
No study locations are listed for this record.
The record gives a start of May 1991, a primary completion of May 1992 and a completion of Aug 1992. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2009, 17 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan